| Gene symbol | TNFRSF17 | Synonyms | BCM, BCMA, CD269, TNFRSF13A | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p13.13 | dbXrefs | |
| Description | TNF receptor superfamily member 17 | ||||
| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC3435 |
| Trial ID | NCT05850234 |
| Disease | Multiple Myeloma |
| Altered gene | CD19|BCMA |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | GC012F |
| Phase | Phase1|Phase2 |
| Recruitment status | Not Recruiting |
| Title | A Study of GC012F, a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma |
| Year | 2023 |
| Country | United States |
| Company sponsor | Gracell Biopharmaceuticals, Inc. |
| Other ID(s) | GC012F-CD19/BCMA-001 |
| Cohort 1 | |||||||
|
|||||||